Hanall Biopharma Statistics

Total Valuation

Hanall Biopharma has a market cap or net worth of KRW 2.01 trillion. The enterprise value is 1.97 trillion.

Market Cap	2.01T
Enterprise Value	1.97T

Important Dates

The last earnings date was Wednesday, November 13, 2024.

Earnings Date	Nov 13, 2024
Ex-Dividend Date	n/a

Share Statistics

Hanall Biopharma has 50.71 million shares outstanding. The number of shares has decreased by -0.33% in one year.

Current Share Class	n/a
Shares Outstanding	50.71M
Shares Change (YoY)	-0.33%
Shares Change (QoQ)	+0.02%
Owned by Insiders (%)	0.21%
Owned by Institutions (%)	18.54%
Float	34.49M

Valuation Ratios

PE Ratio	n/a
Forward PE	92.89
PS Ratio	15.37
PB Ratio	11.79
P/TBV Ratio	n/a
P/FCF Ratio	93.06
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-318.72
EV / Sales	15.14
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	91.45

Financial Position

The company has a current ratio of 3.14, with a Debt / Equity ratio of 0.01.

Current Ratio	3.14
Quick Ratio	2.00
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	0.05
Interest Coverage	-109.31

Financial Efficiency

Return on equity (ROE) is -3.56% and return on invested capital (ROIC) is -2.65%.

Return on Equity (ROE)	-3.56%
Return on Assets (ROA)	-2.11%
Return on Capital (ROIC)	-2.65%
Revenue Per Employee	426.06M
Profits Per Employee	-20.23M
Employee Count	306
Asset Turnover	0.59
Inventory Turnover	2.28

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +12.83% in the last 52 weeks. The beta is 0.84, so Hanall Biopharma's price volatility has been lower than the market average.

Beta (5Y)	0.84
52-Week Price Change	+12.83%
50-Day Moving Average	41,470.00
200-Day Moving Average	36,567.00
Relative Strength Index (RSI)	40.99
Average Volume (20 Days)	969,996

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Hanall Biopharma had revenue of KRW 130.37 billion and -6.19 billion in losses. Loss per share was -122.33.

Revenue	130.37B
Gross Profit	66.63B
Operating Income	-7.42B
Pretax Income	-7.25B
Net Income	-6.19B
EBITDA	-4.16B
EBIT	-7.42B
Loss Per Share	-122.33

Full Income Statement

Balance Sheet

The company has 35.98 billion in cash and 1.15 billion in debt, giving a net cash position of 34.83 billion or 686.93 per share.

Cash & Cash Equivalents	35.98B
Total Debt	1.15B
Net Cash	34.83B
Net Cash Per Share	686.93
Equity (Book Value)	170.30B
Book Value Per Share	3,358.38
Working Capital	62.28B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 23.54 billion and capital expenditures -1.96 billion, giving a free cash flow of 21.58 billion.

Operating Cash Flow	23.54B
Capital Expenditures	-1.96B
Free Cash Flow	21.58B
FCF Per Share	425.53

Full Cash Flow Statement

Margins

Gross margin is 51.10%, with operating and profit margins of -5.69% and -4.75%.

Gross Margin	51.10%
Operating Margin	-5.69%
Pretax Margin	-5.56%
Profit Margin	-4.75%
EBITDA Margin	-3.19%
EBIT Margin	-5.69%
FCF Margin	16.55%

Dividends & Yields

Hanall Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.33%
Shareholder Yield	0.33%
Earnings Yield	-0.31%
FCF Yield	1.07%

Stock Splits

The last stock split was on April 28, 2006. It was a forward split with a ratio of 10.

Last Split Date	Apr 28, 2006
Split Type	Forward
Split Ratio	10

Scores

Hanall Biopharma has an Altman Z-Score of 23.95.

Altman Z-Score	23.95
Piotroski F-Score	n/a